financetom
Business
financetom
/
Business
/
Stellantis exploring deals for Chinese rivals to invest in its business, Bloomberg reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stellantis exploring deals for Chinese rivals to invest in its business, Bloomberg reports
Mar 12, 2026 10:11 AM

March 12 (Reuters) - Stellantis ( STLA ) is exploring

deals with Chinese carmakers whereby they would invest in the

Fiat owner's struggling European operations, Bloomberg News

reported on Thursday.

The carmaker's executives have met with China's Xiaomi ( XIACF )

and Xpeng Inc ( XPEV ) to discuss options for an

overhaul of Stellantis ( STLA ) in Europe, including for the Chinese

companies to acquire stakes in Maserati or other brands, the

report said, citing people familiar with the matter.

"As part of its normal course of business, Stellantis ( STLA ) holds

discussions with a range of industry players around the world on

various topics, always with the ultimate aim of providing

customers with the best mobility choices," a Stellantis ( STLA )

spokesperson told Reuters.

The proposed overhaul might eventually lead to a further

separation between Stellantis' ( STLA ) U.S. and European arms, the

report said, adding that a full breakup is not the focus of

current discussions.

"Stellantis ( STLA ) states in the most categoric terms that there is

no truth in the suggestion that it is considering a plan to

split the Company. Any assertion to the contrary is pure

invention," the spokesperson said.

Xpeng ( XPEV ) and Xiaomi ( XIACF ) did not immediately respond to requests for

comment. Reuters could not verify the report.

Western automakers have been juggling investment between

electric vehicles and petrol models while contending with

fast-rising Chinese rivals and higher trade barriers.

Stellantis ( STLA ), created through the merger of Fiat Chrysler and

Peugeot maker PSA, last month announced 22.2 billion euros

($26.4 billion) in charges, scaling back its EV ambitions as

Europe waters down emissions targets in a move that would allow

combustion engines to stay around for longer.

Several Chinese carmakers have made moves to set up

production in Europe. Chinese automaker Leapmotor will

build vehicles at a Stellantis ( STLA ) plant in Spain as part of a joint

venture.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Is CEL-SCI Stock Crashing After-Hours?
Why Is CEL-SCI Stock Crashing After-Hours?
Aug 28, 2025
CEL-SCI Corporation ( CVM ) shares tumbled 38.19% in after-hours trading to $8.06 on Tuesday following the cancer immunotherapy company’s announcement of a $10 million public offering priced below current market levels. Check out the current price of CVM stock here.  Offering Details Drive Share Price Volatility The clinical-stage company priced 1,111,200 common shares at $9.00 each, representing a 30.9%...
Berkshire raises stake in Japan's Mitsubishi above 10%
Berkshire raises stake in Japan's Mitsubishi above 10%
Aug 28, 2025
TOKYO, Aug 28 (Reuters) - Berkshire Hathaway ( BRK/A ), through its wholly-owned unit National Indemnity Company, has raised its stake in Japan's Mitsubishi Corp ( MSBHF ) and Mitsui & Co ( MITSF ) , the companies said on Thursday. Berkshire raised its stake in Mitsubishi ( MSBHF ) to 10.23% from 9.74% previously, the company said in a...
Cel-Sci Prices $10 Million Stock Offering
Cel-Sci Prices $10 Million Stock Offering
Aug 28, 2025
03:22 AM EDT, 08/28/2025 (MT Newswires) -- Cel-Sci ( CVM ) said late Wednesday it priced a public offering of about 1.1 million common shares at $9 per share for expected gross proceeds of about $10 million. Net proceeds will be used for the company's drug development program, working capital and general corporate purposes, it said. Closing of the offering...
Australia's Telix Pharma says FDA seeks more data on cancer diagnostic drug; shares plunge
Australia's Telix Pharma says FDA seeks more data on cancer diagnostic drug; shares plunge
Aug 28, 2025
Aug 28 (Reuters) - The U.S. Food and Drug Administration (FDA) sought more data from Telix Pharmaceuticals ( TLX ) on its drug to detect a form of kidney cancer, the Australian cancer diagnostics firm said on Thursday. Telix's Sydney-listed shares plunged as much as 24%, its worst intraday fall on record. It ended 18.8% lower at A$14.95 and was...
Copyright 2023-2026 - www.financetom.com All Rights Reserved